NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Up 90.3% in September

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totaling 56,900 shares, a growth of 90.3% from the September 15th total of 29,900 shares. Based on an average daily trading volume, of 368,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 368,400 shares, the short-interest ratio is presently 0.2 days.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NMTC. Warberg Asset Management LLC bought a new position in shares of NeuroOne Medical Technologies in the second quarter valued at about $27,000. Focus Financial Network Inc. bought a new stake in NeuroOne Medical Technologies during the 3rd quarter worth about $31,000. XTX Topco Ltd bought a new stake in NeuroOne Medical Technologies during the 2nd quarter worth about $51,000. Cambridge Investment Research Advisors Inc. bought a new stake in NeuroOne Medical Technologies during the 1st quarter worth about $69,000. Finally, Goldman Sachs Group Inc. bought a new stake in NeuroOne Medical Technologies during the 1st quarter worth about $84,000. 16.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

NMTC has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “hold” rating in a research note on Friday, October 3rd. Maxim Group began coverage on NeuroOne Medical Technologies in a report on Tuesday, September 9th. They set a “buy” rating and a $3.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.23.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ NMTC opened at $0.77 on Thursday. The stock has a market cap of $38.51 million, a PE ratio of -5.13 and a beta of 0.71. The business has a fifty day moving average of $0.86 and a two-hundred day moving average of $0.73. NeuroOne Medical Technologies has a 52-week low of $0.40 and a 52-week high of $1.39.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. NeuroOne Medical Technologies had a negative return on equity of 163.49% and a negative net margin of 55.44%.The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $1.82 million. NeuroOne Medical Technologies has set its FY 2025 guidance at EPS.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.